Since legislative reforms in late 2016, Australian patients have been able to access medicinal cannabis products through the TGA’s Special Access Scheme and Authorised Prescriber scheme or through participation in a clinical trial.
Clinical research trials in Australia are working towards evidence-based results to support the entry of medicinal cannabis products onto the Australian Register of Therapeutic Goods. This means any doctor will be able to prescribe those medicinal cannabis products.
Many patients are not aware that different genetic strains of medicinal cannabis contain varying levels of bio-active molecules such as THC, CBD and many others.
Cann Group is committed to support the work of the medicinal community as they strive to understand how these different bio-active substances work and interact with the human endocannabinoid system.